Growth hormone releasing peptides: Physiology and clinical applications

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 3, 2000, Pages 168-174

  Bowers, C Y ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; COMPLEMENTARY DNA; GHRELIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; MESSENGER RNA; NEUROPEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; GROWTH HORMONE RELEASE; HUMAN; NEUROENDOCRINOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034082868     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200006000-00011     Document Type: Review

References (30)

1. 1 Bowers CY: Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci 1998, 54:1316-1329.
2. 2 Smith RG, Feighner S, Prendergast K, et al.: A new orphan receptor involved in pulsatile growth hormone release. TEM 1999, 10:128-135.
3. 3 Ghigo E, Boghen M, Casanueva FF, Dieguez C (Eds). Growth Hormone Secretagogues: Basic Findings and Clinical Implications. Amsterdam: Elsevier Science 1999:1-25.
4. 4 Kojima M, Hosada H, Date Y, et al.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660. First report of the natural GHRP, ghrelin, with details of isolation, purification, and characterization in rats and humans.
5. 5 Korbonits M, Little JA, Forsling ML, et al.: The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol 1999, 11:532-528.
6. 6 Bailey ART, Giles ME, Brown CH, et al.: Chronic central infusion of growth hormone secretagogues: effects on fos expression and peptide gene expression in the rat arcuate nucleus. Neuroendocrinol 1999, 70:83-92.
7. 7 Bowers CY, Granda-Ayala R, Parulkar A, et al.: Impact of GHRP-2 infusion for 30-90 days in older men and women with decreased GH secretion. 81st Annual Meeting of the Endocrine Society, San Diego, June 1999:571.
8. 8 Honda K, Bailey ART, Bull PM, et al.: An electrophysiological and morphological investigation of the projections of growth hormone releasing peptide-6 responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus. Neurosci 1999, 90:875-883.
9. 9 Willesen, MG, Kristensen P, Romer J: Co-localization of growth hormone secretagogue receptor and NPY and mRNA in the arcuate nucleus of the rat. Neuroendocrinol 1999, 70:306-316.
10. 10 Luckman SM, Rosenzweig I, Dickson SL: Activation of arcuate nucleus neurons by systemic administration of leptin and growth hormone releasing peptide-6 in normal and fasted rats. Neuroendocrinol 1999, 70:93-100.
11. 11 Kineman RD, Kamegai J, Frohman LA: Growth hormone (GH) releasing hormone (GHRH) and the GH secretagogue (GHS), L692,585, differentially modulate rat pituitary GHS receptor and GHRH receptor messenger ribonucleic acid levels. Endocrinol 1999, 140:3581-3586.
12. 12 Kamegai J, Wakabayashi I, Kineman RD, Frohman LA: Growth hormone releasing hormone receptor (GHRH-R) and growth hormone secretagogue receptor (GHS-R) mRNA levels during postnatal development in male and female rats. J Neuroendocrinol 1999, 11:299-306.
13. 13 Bisi G, Podio V, Valetto MR, et al.: Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 1999, 22:266-272.
14. 14 Locatelli V, Rossoni G, Schweiger F, et al.: Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinol 1999, 140:4024-4031.
15. 15 Bisi G, Podio V, Valetto MR, et al.: Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999, 381:31-38.
16. 16 Tivesten A, Bollano E, Caidahl K, et al.: The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinol 2000, 141:60-66.
17. 17 Bodart V, Bouchard JF, McNicoll N, et al.: Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 1999, 85:796-802.
18. 18 Gasperi M, Aimaretti G, Scarcello G, et al.: Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. J Clin Endocrinol Metab 1999, 84:2633-2637.
19. 19 Peino R, Leal A, Garcia-Mayor RV, et al.: The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans. Growth Hormone IGF Res 1999, 9:101-105.
20. 20 Korbonits M, Ciccarelli E, Ghigo E, Grossman AB: The growth hormone secretagogue receptor. Growth Hormone IGF Res 1999, 9:93-99.
21. 21 Van den Berghe G, Wouters P, Weekers F, et al.: Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999, 84:1311-1323.
22. 22 Shah N, Evans WS, Bowers CY, Veldhuis JD: Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms. J Clin Endocrinol Metab 1999, 84:2140-2150.
23. 23 Svensson J, Jansson JO, Ottosson M, et al.: Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). J Clin Endocrinol Metab 1999, 84:2028-2033.
24. 24 Jenkins RC, El Nahas AM, Wilkie ME, et al.: The effects of dose, nutrition and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis. J Clin Endocrinol Metab 1999, 84:1220-1225.
25. 25 Meacham LR, Culler FL, Abdul-Latif H, et al.: Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy. Metabolism 1999, 48:585-589.
26. 26 Rahim A, O'Neill PA, Shalet SM: The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol 1999, 50:77-84.
27. 27 Korbonits M, Kaltsas G, Perry LA, et al.: The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999, 84:2489-2495.
28. 28 Ghigo E, Gianotti L, Arvat E, et al.: Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans. J Clin Endocrinol Metab 1999, 84:285-290.
29. 29 Arvat E, Ramunni J, Maccagno B, et al.: Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease. Neuroendocrinol 1999, 70:200-206.
30. 30 Bowers CY: GHRP: unnatural toward the natural. In: Growth Hormone Secretagogues: Basic Findings and Clinical Implications. Edited by Ghigo E, Boghen M, Casanueva FF, Dieguez C. Amsterdam: Elsevier Science, 1999:5-18.